[EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
Zalcman
Gérard
G
Service de pneumologie, ER13 INSERM Cancer & Populations Université de Caen Basse-Normandie, UFR de médecine 14032 Caen Cedex.
D001984:Bronchial Neoplasms / Q000188:drug therapy / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics; D004815:Epidermal Growth Factor / Q000187:drug effects / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D018734:Genes, erbB-2 / Q000187:drug effects; D011905:Genes, ras / Q000187:drug effects; D006801:Humans; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D011799:Quinazolines / Q000494:pharmacology; D020545:Respiratory Mucosa / Q000187:drug effects
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D004815:Epidermal Growth Factor; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases